Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Puma Biotechnology total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Puma Biotechnology's total debt was $0 at Jun 30, 2026. For fiscal 2025 it was $22.52M, down 66.4% from the year before. The highest annual figure on record is $99.66M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.52M | -66.4% |
| FY2024 | Dec 31, 2024 | $67.05M | -32.7% |
| FY2023 | Dec 31, 2023 | $99.66M | +1.4% |
| FY2022 | Dec 31, 2022 | $98.31M | +1.3% |
| FY2021 | Dec 31, 2021 | $97.09M | -1.2% |
| FY2020 | Dec 31, 2020 | $98.31M | +3.5% |
| FY2019 | Dec 31, 2019 | $94.96M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $11.28M | -79.8% |
| Q4 FY2025 | Dec 31, 2025 | $22.52M | -66.4% |
| Q3 FY2025 | Sep 30, 2025 | $33.72M | -56.8% |
| Q2 FY2025 | Jun 30, 2025 | $44.87M | -49.6% |
| Q1 FY2025 | Mar 31, 2025 | $55.98M | -44.0% |
| Q4 FY2024 | Dec 31, 2024 | $67.05M | -32.7% |
| Q3 FY2024 | Sep 30, 2024 | $78.08M | -21.4% |
| Q2 FY2024 | Jun 30, 2024 | $89.06M | -10.0% |
| Q1 FY2024 | Mar 31, 2024 | $100.02M | +1.4% |
| Q4 FY2023 | Dec 31, 2023 | $99.66M | +1.4% |
| Q3 FY2023 | Sep 30, 2023 | $99.30M | +1.3% |
| Q2 FY2023 | Jun 30, 2023 | $98.95M | +1.3% |
| Q1 FY2023 | Mar 31, 2023 | $98.62M | +1.3% |
| Q4 FY2022 | Dec 31, 2022 | $98.31M | +1.3% |
| Q3 FY2022 | Sep 30, 2022 | $97.99M | +1.2% |
| Q2 FY2022 | Jun 30, 2022 | $97.68M | -2.4% |
| Q1 FY2022 | Mar 31, 2022 | $97.38M | -1.8% |
| Q4 FY2021 | Dec 31, 2021 | $97.09M | -1.2% |
| Q3 FY2021 | Sep 30, 2021 | $96.80M | -0.6% |
| Q2 FY2021 | Jun 30, 2021 | $100.14M | +5.4% |
| Q1 FY2021 | Mar 31, 2021 | $99.20M | – |
| Q4 FY2020 | Dec 31, 2020 | $98.31M | – |
| Q3 FY2020 | Sep 30, 2020 | $97.43M | – |
| Q4 FY2019 | Dec 31, 2019 | $94.96M | – |
See a number that looks wrong?